1309 related articles for article (PubMed ID: 9146930)
1. Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages.
Gosset P; Tillie-Leblond I; Malaquin F; Durieu J; Wallaert B; Tonnel AB
Clin Exp Allergy; 1997 Apr; 27(4):379-88. PubMed ID: 9146930
[TBL] [Abstract][Full Text] [Related]
2. Effects of TNFalpha on the human nasal mucosa in vivo.
Widegren H; Korsgren M; Andersson M; Greiff L
Respir Med; 2007 Sep; 101(9):1982-7. PubMed ID: 17532197
[TBL] [Abstract][Full Text] [Related]
3. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge.
Wagenmann M; Schumacher L; Bachert C
Allergy; 2005 Sep; 60(9):1132-8. PubMed ID: 16076297
[TBL] [Abstract][Full Text] [Related]
4. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis.
Weido AJ; Reece LM; Alam R; Cook CK; Sim TC
Ann Allergy Asthma Immunol; 1996 Nov; 77(5):407-15. PubMed ID: 8933780
[TBL] [Abstract][Full Text] [Related]
5. [Myeloperoxidase (MPO) as a marker of neutrophil influx into nasal mucosa after recombinant IL-8 challenge].
Kupczyk M; Bocheńska-Marciniak M; Górski P; Kuna P
Pneumonol Alergol Pol; 2002; 70(11-12):544-9. PubMed ID: 12884563
[TBL] [Abstract][Full Text] [Related]
6. Mediator release of neuropeptides after nasal provocation in perennial allergic rhinitis patients.
Gawlik R; DuBuske L
Rhinology; 2010 Jun; 48(2):206-10. PubMed ID: 20502762
[TBL] [Abstract][Full Text] [Related]
7. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge.
Erin EM; Zacharasiewicz AS; Nicholson GC; Tan AJ; Higgins LA; Williams TJ; Murdoch RD; Durham SR; Barnes PJ; Hansel TT
Clin Exp Allergy; 2005 Dec; 35(12):1608-14. PubMed ID: 16393327
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and interleukin-1 alpha production is associated with antigen-induced late nasal response.
Gosset P; Malaquin F; Delneste Y; Wallaert B; Capron A; Joseph M; Tonnel AB
J Allergy Clin Immunol; 1993 Dec; 92(6):878-90. PubMed ID: 8258622
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 17 and RANTES levels in induced sputum of patients with allergic rhinitis after a single nasal allergen challenge.
Semik-Orzech A; Barczyk A; Wiaderkiewicz R; Pierzchala W
Ann Allergy Asthma Immunol; 2009 Nov; 103(5):418-24. PubMed ID: 19927541
[TBL] [Abstract][Full Text] [Related]
10. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G
Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils, specific hyperreactivity and occurrence of late phase reaction in allergic rhinitis.
Milanese M; Ricca V; Canonica GW; Ciprandi G
Eur Ann Allergy Clin Immunol; 2005 Jan; 37(1):7-10. PubMed ID: 15745370
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor in allergen-induced nasal inflammation.
Choi GS; Park HJ; Hur GY; Choi SJ; Shin SY; Ye YM; Park HS
Clin Exp Allergy; 2009 May; 39(5):655-61. PubMed ID: 19236408
[TBL] [Abstract][Full Text] [Related]
13. Effect of topical levocabastine on nasal response to allergen challenge and nasal hyperreactivity in perennial rhinitis.
de Graaf-in 't Veld T; Garrelds IM; van Toorenenbergen AW; Mulder PG; Gerth van Wijk R; Boegheim JP
Ann Allergy Asthma Immunol; 1995 Sep; 75(3):261-6. PubMed ID: 7552929
[TBL] [Abstract][Full Text] [Related]
14. [Humoral mucosal immunity in allergic rhinitis].
Kramer MF; Jordan TR; Pfrogner E; Rasp G
Laryngorhinootologie; 2005 Jul; 84(7):503-10. PubMed ID: 16010632
[TBL] [Abstract][Full Text] [Related]
15. Diminished response to grass pollen allergen challenge in subjects with concurrent house dust mite allergy.
Reinartz SM; van Ree R; Versteeg SA; Zuidmeer L; van Drunen CM; Fokkens WJ
Rhinology; 2009 Jun; 47(2):192-8. PubMed ID: 19593978
[TBL] [Abstract][Full Text] [Related]
16. Nasal challenge with allergen leads to maxillary sinus inflammation.
Baroody FM; Mucha SM; Detineo M; Naclerio RM
J Allergy Clin Immunol; 2008 May; 121(5):1126-1132.e7. PubMed ID: 18367240
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication.
Akerlund A; Andersson M; Leflein J; Lildholdt T; Mygind N
J Allergy Clin Immunol; 2005 Mar; 115(3 Suppl 1):S460-82. PubMed ID: 15746883
[TBL] [Abstract][Full Text] [Related]
18. IL-13 is essential to the late-phase response in allergic rhinitis.
Miyahara S; Miyahara N; Matsubara S; Takeda K; Koya T; Gelfand EW
J Allergy Clin Immunol; 2006 Nov; 118(5):1110-6. PubMed ID: 17088137
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of IL-6, IL-8, and GM-CSF release in nasal secretions of allergic patients after nasal challenge.
Ohkubo K; Ikeda M; Pawankar R; Gotoh M; Yagi T; Okuda M
Rhinology; 1998 Dec; 36(4):156-61. PubMed ID: 9923057
[TBL] [Abstract][Full Text] [Related]
20. Role of sphingosine 1-phosphate receptor expression in eosinophils of patients with allergic rhinitis, and effect of topical nasal steroid treatment on this receptor expression.
Mackle T; Gendy SS; Walsh M; McConn-Walsh R; Costello RW; Walsh MT
J Laryngol Otol; 2008 Dec; 122(12):1309-17. PubMed ID: 18808729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
